The potency of these MMAF-based ADCs was confirmed on melanoma cells that overexpress the receptor tyrosine-protein kinase erbB-3, which is also known as HER3 (HER3 allows the escape of tumor cells from vemurafenib-targeted treatment of BRAF-positive melanoma cells) [1,16,33]. The gene discussed is BRAF; the disease is neoplasm.